ASX news
Optiscan Imaging (ASX:OIL) has unveiled its next generation microscopic medical imaging device known as InForm, specifically designed to transform pathology workflows by delivering real-time digital insights at point of contact with a tissue sample.
🔹Improves efficiency and accuracy of analysis and diagnosis across all pathology workflows.
🔹Expands Optiscan’s product portfolio into the pathology market, marking a pivotal milestone in advancing the company`s strategic objectives.
🔹Enhances the entire pathology workflow across a range of settings, enabling efficiencies and on-the-spot digital decision making for pathologists to improve diagnostic capabilities.
“The reveal of our revolutionary InForm™ device, the latest addition to our ever-expanding suite of hardware products, represents a significant advancement in the evolution of digital pathology. InForm™ has the ability to enhance the entire pathology workflow from bedside to laboratory and beyond, by improving the speed, accuracy and flexibility of testing, analysis and diagnosis." - Optiscan CEO and Managing Director, Dr Camile Farah

Optiscan Imaging (ASX:OIL) has unveiled its next generation microscopic medical imaging device known as InForm, specifically designed to transform pathology workflows by delivering real-time digital insights at point of contact with a tissue sample.
🔹Improves efficiency and accuracy of analysis and diagnosis across all pathology workflows.
🔹Expands Optiscan’s product portfolio into the pathology market, marking a pivotal milestone in advancing the company`s strategic objectives.
🔹Enhances the entire pathology workflow across a range of settings, enabling efficiencies and on-the-spot digital decision making for pathologists to improve diagnostic capabilities.
“The reveal of our revolutionary InForm™ device, the latest addition to our ever-expanding suite of hardware products, represents a significant advancement in the evolution of digital pathology. InForm™ has the ability to enhance the entire pathology workflow from bedside to laboratory and beyond, by improving the speed, accuracy and flexibility of testing, analysis and diagnosis." - Optiscan CEO and Managing Director, Dr Camile Farah
...
Baby goods retailer Baby Bunting (ASX: BBN) has reported a boost in profitability in the first half of the 2025 financial year driven by an uptick in sales, a rise in new customer acquisitions, and gross margin expansion. The company is implementing a series of strategic initiatives to fuel further growth.
👶 Net profit after tax (NPAT) of $4.8 million on a pro-forma basis up by 37% from same time last year as new customer acquisitions rise by 12%
🍼 Gross margin expands by 260 basis points to 39.8 per cent with the company on track to meet its margin target for the full financial year
🧸 Progresses new store rollout and refurbishment of existing shops to fuel growth
“Our focus on driving sales through range innovation and new customer acquisition is delivering results. Newness in our ranges continues to resonate, with new customer acquisition up 12% on the prior period. Our exclusive branded products remain a key traffic driver and, with a strong pipeline of exclusive launches in the second half, we expect this momentum to continue.” – Mark Teperson, Baby Bunting Chief Executive Officer

Baby goods retailer Baby Bunting (ASX: BBN) has reported a boost in profitability in the first half of the 2025 financial year driven by an uptick in sales, a rise in new customer acquisitions, and gross margin expansion. The company is implementing a series of strategic initiatives to fuel further growth.
👶 Net profit after tax (NPAT) of $4.8 million on a pro-forma basis up by 37% from same time last year as new customer acquisitions rise by 12%
🍼 Gross margin expands by 260 basis points to 39.8 per cent with the company on track to meet its margin target for the full financial year
🧸 Progresses new store rollout and refurbishment of existing shops to fuel growth
“Our focus on driving sales through range innovation and new customer acquisition is delivering results. Newness in our ranges continues to resonate, with new customer acquisition up 12% on the prior period. Our exclusive branded products remain a key traffic driver and, with a strong pipeline of exclusive launches in the second half, we expect this momentum to continue.” – Mark Teperson, Baby Bunting Chief Executive Officer
...
Australian retailer Adore Beauty (ASX: ABY) has reported a sharp rise in profitability and margin growth in the first half of FY25 as its refreshed operational strategy focused on disciplined cost management and the expansion of its retail network begins to take shape.
💄 Operating earnings (EBIT) of $2.8 million in H1 FY25 up by 126% from same time last year
🧴 Delivers cash flow positive half-year and record gross margin of 36.2%
💅 Launches physical store roll out with opening of first shop in Victoria as it targets national retail network of 25 shops
“Our half-year results demonstrate the strength of the Adore Beauty brand and the early momentum of our strategy refresh focusing in the near-term on enhancing quality of earnings and optimising our operating model. I am delighted with the demonstrated gains in gross margin which delivered material improvement and the subsequent 126% growth in EBIT in the half.” – Sacha Laing, Adore Beauty Chief Executive Officer

Australian retailer Adore Beauty (ASX: ABY) has reported a sharp rise in profitability and margin growth in the first half of FY25 as its refreshed operational strategy focused on disciplined cost management and the expansion of its retail network begins to take shape.
💄 Operating earnings (EBIT) of $2.8 million in H1 FY25 up by 126% from same time last year
🧴 Delivers cash flow positive half-year and record gross margin of 36.2%
💅 Launches physical store roll out with opening of first shop in Victoria as it targets national retail network of 25 shops
“Our half-year results demonstrate the strength of the Adore Beauty brand and the early momentum of our strategy refresh focusing in the near-term on enhancing quality of earnings and optimising our operating model. I am delighted with the demonstrated gains in gross margin which delivered material improvement and the subsequent 126% growth in EBIT in the half.” – Sacha Laing, Adore Beauty Chief Executive Officer
...
Ahead of appearing at the Stocks On Track event, Kingston Resources (ASX:KSN) Managing Director Andrew Corbett speaks with The Stock Network`s Lel Smits and highlights:
⛏️ Rising gold price and operations
⚒️ Maiden underground Ore Reserve at Mineral Hill
⛰️ Mineral Hill upside

Ahead of appearing at the Stocks On Track event, Kingston Resources (ASX:KSN) Managing Director Andrew Corbett speaks with The Stock Network`s Lel Smits and highlights:
⛏️ Rising gold price and operations
⚒️ Maiden underground Ore Reserve at Mineral Hill
⛰️ Mineral Hill upside
...
Medical technology business Artrya (ASX: AYA) has pocketed $15 million from a placement as it looks to fast track the commercialisation of its patented Salix artificial intelligence (AI) platform used to detect heart disease.
⚕️ Proceeds will be used to accelerate regulatory approvals in the lucrative US market, as well as customer implementation, clinical studies, and regulatory costs
🧑⚕️ Clearance from the US Food and Drug Administration (FDA) expected soon
🏥 Adds to recent contract win with Australia’s second largest diagnostic imaging provider, Sonic Healthcare
“The Company continues the regulatory pathway to expand FDA approvals this year with a portion of Placement proceeds applied to accelerate regulatory applications for our SCP & SCF products, along with customer implementation costs including the Sonic Healthcare Australia Radiology commercial agreement announced on 12 February 2025.” – Mathew Regan, Artrya Chief Executive Officer

Medical technology business Artrya (ASX: AYA) has pocketed $15 million from a placement as it looks to fast track the commercialisation of its patented Salix artificial intelligence (AI) platform used to detect heart disease.
⚕️ Proceeds will be used to accelerate regulatory approvals in the lucrative US market, as well as customer implementation, clinical studies, and regulatory costs
🧑⚕️ Clearance from the US Food and Drug Administration (FDA) expected soon
🏥 Adds to recent contract win with Australia’s second largest diagnostic imaging provider, Sonic Healthcare
“The Company continues the regulatory pathway to expand FDA approvals this year with a portion of Placement proceeds applied to accelerate regulatory applications for our SCP & SCF products, along with customer implementation costs including the Sonic Healthcare Australia Radiology commercial agreement announced on 12 February 2025.” – Mathew Regan, Artrya Chief Executive Officer
...
Health and fitness club provider Viva Leisure (ASX: VVA) has delivered a strong set of numbers for the first half of the 2025 financial year with membership growth and network expansion propelling revenue and profitability to record levels.
🏋️ Revenue up by 25% from the same time last year as memberships soar by 72%
💪 Operating earnings (EBITDA) up by 26% year-on-year with net profit after tax up by 15%
🏃♀️ Prioritising free cash flow generation, network optimisation, and expansion of technology-driven offerings to drive further growth
“1H FY25 has been a phenomenal period for Viva Leisure, with record-breaking results reflecting the strength of our diversified strategy and the resilience of our business model. Our expanding corporate and franchise network, combined with our high-margin technology and payments division, continues to drive sustainable and profitable growth.” – Harry Konstantinou, Viva Leisure Chief Executive Officer and Managing Director

Health and fitness club provider Viva Leisure (ASX: VVA) has delivered a strong set of numbers for the first half of the 2025 financial year with membership growth and network expansion propelling revenue and profitability to record levels.
🏋️ Revenue up by 25% from the same time last year as memberships soar by 72%
💪 Operating earnings (EBITDA) up by 26% year-on-year with net profit after tax up by 15%
🏃♀️ Prioritising free cash flow generation, network optimisation, and expansion of technology-driven offerings to drive further growth
“1H FY25 has been a phenomenal period for Viva Leisure, with record-breaking results reflecting the strength of our diversified strategy and the resilience of our business model. Our expanding corporate and franchise network, combined with our high-margin technology and payments division, continues to drive sustainable and profitable growth.” – Harry Konstantinou, Viva Leisure Chief Executive Officer and Managing Director
...
If you like to buy at Chemist Warehouse you may be interested to know that from today, it today became part of a listed company. Sigma Healthcare is the listed company that merged with Chemist Warehouse, debuting today as a merged entity trading under the code SIG.

If you like to buy at Chemist Warehouse you may be interested to know that from today, it today became part of a listed company. Sigma Healthcare is the listed company that merged with Chemist Warehouse, debuting today as a merged entity trading under the code SIG. ...
Diversified digital health platform business Vitura Health (ASX: VIT) has sealed $5.1 million from a strategic placement to fund its new acquisition of leading Australian medicinal cannabis clinic business, Candor Medical.
🧑⚕️ Propels Vitura into one of Australia’s largest medicinal cannabis clinic providers by growing its consolidated consultation numbers to more than 100,000 each year
💊 Expands Vitura’s specialty healthcare division with the deal expected to deliver a material boost to revenue and operating earnings (EBITDA)
🥼 Backed by $5.1 million placement to an entity associated with renowned high-net-worth businessman, Professor Khalil Shahin
“We are very excited by the opportunities unlocked by this acquisition which we see as a great opportunity to bring together two leaders in the field, both of whom have a deep alignment on the commitment to providing patients with personalised care and which reinforces our goal to make specialty healthcare product and service verticals more accessible to millions of patients across Australia.” – Geoff Cockerill, Vitura Health Chief Executive Officer

Diversified digital health platform business Vitura Health (ASX: VIT) has sealed $5.1 million from a strategic placement to fund its new acquisition of leading Australian medicinal cannabis clinic business, Candor Medical.
🧑⚕️ Propels Vitura into one of Australia’s largest medicinal cannabis clinic providers by growing its consolidated consultation numbers to more than 100,000 each year
💊 Expands Vitura’s specialty healthcare division with the deal expected to deliver a material boost to revenue and operating earnings (EBITDA)
🥼 Backed by $5.1 million placement to an entity associated with renowned high-net-worth businessman, Professor Khalil Shahin
“We are very excited by the opportunities unlocked by this acquisition which we see as a great opportunity to bring together two leaders in the field, both of whom have a deep alignment on the commitment to providing patients with personalised care and which reinforces our goal to make specialty healthcare product and service verticals more accessible to millions of patients across Australia.” – Geoff Cockerill, Vitura Health Chief Executive Officer
...
BTC Health (ASX:BTC) has appointed Salesh Balak as Chief Financial Officer and Company Secretary, effective 17 March 2025. It has also appointed its current Head of Finance, Josh Kahanovitz, into the role of Chief Operating Officer.
🥼 Mr Balak joins BTC Health from Universal Biosensors Australia where he was the Chief Financial Officer and Company Secretary for more than 18 years
🩺 He is a member of the Institute of Chartered Accountants and Certified Practicing Accountants
💉 The appointment reflects the underlying expansion of the BTC Health business
“I am delighted to welcome Salesh to BTC. He brings significant international experience applicable to high-growth companies in the healthcare and medical sectors. He joins us at an exciting time in BTC’s growth journey and he will be a valuable addition to the leadership team.” - BTC Health Executive Chairman Dr Richard Treagus

BTC Health (ASX:BTC) has appointed Salesh Balak as Chief Financial Officer and Company Secretary, effective 17 March 2025. It has also appointed its current Head of Finance, Josh Kahanovitz, into the role of Chief Operating Officer.
🥼 Mr Balak joins BTC Health from Universal Biosensors Australia where he was the Chief Financial Officer and Company Secretary for more than 18 years
🩺 He is a member of the Institute of Chartered Accountants and Certified Practicing Accountants
💉 The appointment reflects the underlying expansion of the BTC Health business
“I am delighted to welcome Salesh to BTC. He brings significant international experience applicable to high-growth companies in the healthcare and medical sectors. He joins us at an exciting time in BTC’s growth journey and he will be a valuable addition to the leadership team.” - BTC Health Executive Chairman Dr Richard Treagus
...
Healthcare technology business Alcidion (ASX: ALC) has sealed a $5.5 million agreement with the Hywel Dda University Health Board in Wales for the provision of its Miya Precision Platform.
⚕️ Represents Alcidion’s first contract win with a Health Board in Wales
🧑⚕️ Hywel Dda provides primary, secondary and community and dental health services to about 380,000 people in Wales
🏥 Miya Precision Platform helps optimise resource allocation, provides clearer insights into vital signs in patients, and streamlines their journeys
“Introducing Alcidion’s Miya Precision Platform will support Hywel Dda to centralise and digitise essential patient information, optimising multiple inputs of clinical information and patient care metrics across its diverse service network to support improved patient flow and capacity management as well as clinical management of deteriorating patients.” – Kate Quirke, Alcidion Chief Executive Officer and Managing Director

Healthcare technology business Alcidion (ASX: ALC) has sealed a $5.5 million agreement with the Hywel Dda University Health Board in Wales for the provision of its Miya Precision Platform.
⚕️ Represents Alcidion’s first contract win with a Health Board in Wales
🧑⚕️ Hywel Dda provides primary, secondary and community and dental health services to about 380,000 people in Wales
🏥 Miya Precision Platform helps optimise resource allocation, provides clearer insights into vital signs in patients, and streamlines their journeys
“Introducing Alcidion’s Miya Precision Platform will support Hywel Dda to centralise and digitise essential patient information, optimising multiple inputs of clinical information and patient care metrics across its diverse service network to support improved patient flow and capacity management as well as clinical management of deteriorating patients.” – Kate Quirke, Alcidion Chief Executive Officer and Managing Director
...
Medication management specialist Careteq (ASX: CTQ) has entered a strategic partnership with MedicAlert Foundation Australia designed to improve medication safety for Australians living with complex health conditions.
⚕️ Enhances access to critical healthcare services offered by both organisations, including Careteq`s Home Medication Reviews (HMRs)
🧑⚕️ Careteq`s clients to benefit from MedicAlert`s life-saving medical identification products and around-the-clock emergency response hotline
💊 Addresses shortfall of more than 500,000 at-risk individuals who don’t receive the medication reviews they require
“Our partnership with MedicAlert aligns perfectly with our goal of preventing medication-related harm. By raising awareness of the benefits of HMRs, we hope to enhance health outcomes for all Australians.” – Mark Simari, Careteq Executive Chairman

Medication management specialist Careteq (ASX: CTQ) has entered a strategic partnership with MedicAlert Foundation Australia designed to improve medication safety for Australians living with complex health conditions.
⚕️ Enhances access to critical healthcare services offered by both organisations, including Careteq`s Home Medication Reviews (HMRs)
🧑⚕️ Careteq`s clients to benefit from MedicAlert`s life-saving medical identification products and around-the-clock emergency response hotline
💊 Addresses shortfall of more than 500,000 at-risk individuals who don’t receive the medication reviews they require
“Our partnership with MedicAlert aligns perfectly with our goal of preventing medication-related harm. By raising awareness of the benefits of HMRs, we hope to enhance health outcomes for all Australians.” – Mark Simari, Careteq Executive Chairman
...
PARKD (ASX: PKD) has sealed an exclusive licencing agreement with Fielders Steel Roofing - a division of BlueScope Steel - for the IP related to its innovative metal decking support bracket (MDSB) and metal deck support system (MDSS) used in the construction of car parks and other commercial structures.
🏗️ Grants Fielders an exclusive five year licence to manufacture, market, distribute, and sell the MDSB and MDSS within Australia
🧱 Creates confidence for immediate go-to-market strategy in Australia and expands PARKD’s addressable market and possible applications of its IP
🔨 Fielders has first right to negotiate additional licences for targeted international markets including the US, New Zealand, Indonesia, Japan, and India
“PARKD recognised the potential, its simple, yet ingenious connection system could present to the broader construction market. This small yet critical invention is the key to unlock the aspirations of the construction sector to meaningfully improve safety, productivity, costs and particularly sustainability goals of the government and private sectors.” – Peter McUtchen, PARKD Managing Director

PARKD (ASX: PKD) has sealed an exclusive licencing agreement with Fielders Steel Roofing - a division of BlueScope Steel - for the IP related to its innovative metal decking support bracket (MDSB) and metal deck support system (MDSS) used in the construction of car parks and other commercial structures.
🏗️ Grants Fielders an exclusive five year licence to manufacture, market, distribute, and sell the MDSB and MDSS within Australia
🧱 Creates confidence for immediate go-to-market strategy in Australia and expands PARKD’s addressable market and possible applications of its IP
🔨 Fielders has first right to negotiate additional licences for targeted international markets including the US, New Zealand, Indonesia, Japan, and India
“PARKD recognised the potential, its simple, yet ingenious connection system could present to the broader construction market. This small yet critical invention is the key to unlock the aspirations of the construction sector to meaningfully improve safety, productivity, costs and particularly sustainability goals of the government and private sectors.” – Peter McUtchen, PARKD Managing Director
...
Get the latest ASX stock market news delivered to your inbox
By proceeding, you can confirm you understand that we handle personal informational in accordance with our Privacy Policy